LDS/Medical Tests/Genetic Testing for Severe Inherited Diseases, NGS

Genetic Testing for Severe Inherited Diseases, NGS

Testing includes cystic fibrosis, Ashkenazi Jewish-associated disorders such as, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease, beta hemoglobinopathies, phenylketonuria and galactosemia.

Cystic fibrosis (CF)

CF is a multisystem, autosomal recessive disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, pulmonary infections, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus (a blockage of the intestine) may occur at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile. Problems with digestion can lead to diarrhea, malnutrition, poor growth, and weight loss. In adolescence or adulthood, a shortage of insulin can cause a form of diabetes known as cystic fibrosis-related diabetes mellitus (CFRDM).

Although over 1500 CFTR mutations have been described that can cause CF, the vast majority of cases are due to the 23 mutations included in the American College of Medical Genetics panel for routine diagnostic and carrier testing. The most common mutation, deltaF508, accounts for approximately 30-80% of the mutations worldwide (depending on the ethnic group studied) Mutations in the CFTR gene disrupt the function of chloride channels, preventing them from regulating the flow of chloride ions and water across cell membranes. As a result, cells that line the passageways of the lungs, pancreas, and other organs produce mucus that is unusually thick and sticky. This mucus clogs the airways and various ducts, causing the characteristic signs and symptoms of cystic fibrosis. The diagnosis of CF is suggested in an infant with elevated trypsinogen on newborn screening or an elevated sweat chloride and confirmed with the identification of biallelic CFTR pathogenic variants.

Ashkenazi Jewish genetic diseases

A group of uncommon disorders that occur more often in people of Eastern European (Ashkenazi) Jewish heritage than in the general population. Even though most of these diseases are severe and can cause early death, some can be treated to reduce symptoms and prolong life. If one or both parents are carriers of a genetic mutation, prenatal diagnosis may be performed by amniocentesis or chorionic villus sampling. in addition to cystic fibrosis, diseases in this group include:

Bloom syndrome (BS)

BS is a rare disorder characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age. Despite their very small head circumference, most affected individuals have normal intellectual ability. Women may be fertile but often have early menopause, and men tend to be infertile, with only one confirmed case of paternity. Serious medical complications that appear in early childhood include chronic obstructive pulmonary disease, diabetes mellitus as a result of insulin resistance, and a wide variety of cancers. It is caused by mutations in the BLM gene resulting in a deficiency or absence of functional BLM protein. BLM protein functions as an anti-recombinase and helps maintain the stability of DNA when the DNA duplexes are unwound during recombination, repair and replication.

Canavan disease (CD)

Most individuals with Canavan disease have the more severe neonatal/infantile form. Affected infants appear normal early in life, but by age three to five months, hypotonia, head lag, macrocephaly, and developmental delays become apparent. With age, children with neonatal/infantile-onset Canavan disease often become irritable and experience sleep disturbance, seizures, and feeding difficulties. Swallowing deteriorates, and some children require nasogastric feeding or permanent feeding gastrostomies. Joint stiffness increases, so that these children resemble individuals with cerebral palsy. Children with mild/juvenile Canavan disease may have normal or mildly delayed speech or motor development early in life without regression. In spite of developmental delay most of these children can be educated in typical classroom settings and may benefit from speech therapy or tutoring as needed. Most children with mild forms of Canavan disease have normal head size, although macrocephaly, retinitis pigmentosa, and seizures have been reported in a few individuals. Canavan disease is caused by mutations in the ASPA gene which reduce the function of aspartoacylase enzyme and severely impair its activity, allowing a compound called N-acetyl-L-aspartic acid (NAA) to accumulate in the neural tissue leading to the progressive destruction of myelin sheaths. Nerves without this protective covering malfunction, disrupting normal brain function and development.

Fanconi anemia (FA) type C

Fanconi anemia type C is an autosomal recessive disease caused by mutations in the FANCC gene. It is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade of life as either leukopenia or thrombocytopenia. Approximately 13% of patients develop acute myeloid leukemia by age 50 years. Solid tumors, particularly of the head and neck, skin, gastrointestinal tract, and genitourinary tract, are also more common in individuals with Fanconi anemia. Mutations in any of the many genes associated with the Fanconi anemia core complex will cause the complex to be nonfunctional and disrupt the entire FA pathway.

Gaucher disease (GBA)

Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene resulting in markedly reduced or absent beta-glucocerebrosidase activity. The lack of glucoscerebrosidase results in the accumulation of glucocerebroside and other glycolipids within the lysosomes of macrophages. The clinical manifestations of GD result from the accumulation of these lipid-laden macrophages in the spleen, liver, bone marrow, bone, and other tissues/organs.

Type 1 Gaucher disease is the most common form of this condition and the clinical features range from mild to severe and may appear anytime from childhood to adulthood. Major signs and symptoms include enlargement of the liver and spleen (hepatosplenomegaly), a low number of red blood cells, easy bruising caused by thrombocytopenia, lung disease, and bone abnormalities such as bone pain, fractures, and arthritis. Types 2 and 3 Gaucher disease are neuronopathic forms of the disorder because they are characterized by problems that affect the central nervous system. In addition to the signs and symptoms described above, these conditions can cause abnormal eye movements, seizures, and brain damage. Type 2 Gaucher disease usually causes life-threatening medical problems beginning in infancy while Type 3 Gaucher disease tends to worsen more slowly than Type 2. The most severe type of Gaucher disease is called the perinatal-lethal form and is characterized by ichthyosis, hepatosplenomegaly; distinctive facial features, serious neurological problems and hydrops fetalis. As its name indicates, most infants with the perinatal lethal form of Gaucher disease survive for only a few days after birth.

Niemann-Pick disease types A and B

Niemann-Pick disease types A and B are caused by mutations in the SMPD1 gene which leads to a deficiency of acid sphingomyelinase. The reduction in sphingomyelinase results in the accumulation of sphingomyelin in cells resulting cell dysfunction and death. Over time, cell loss impairs function of tissues and organs including the brain, lungs, spleen, and liver in people with Niemann-Pick disease types A and B. Type A, the neuropathic form, is the most severe clinically and affected individuals hepatosplenomegaly, and mental degeneration. A classic cherry-red spot of the macula of the retina, which may not be present in the first few months, is eventually present in all affected children. Interstitial lung disease caused by storage of sphingomyelin in pulmonary macrophages results in frequent respiratory infections and often respiratory failure. Most children succumb before the third year. Niemann-Pick Type B individuals have hepatosplenomegaly with progressive hypersplenism and stable liver dysfunction, gradual deterioration in pulmonary function, osteopenia, and an atherogenic lipid profile. Progressive and/or clinically significant neurologic manifestations occur infrequently and survival to adulthood can occur.

Tay-Sachs disease

Tay-Sachs is caused by mutations in the HEXA gene that disrupt the activity of beta-hexosaminidase A and prevent the enzyme from breaking down GM2 ganglioside. As a result, GM2 ganglioside accumulates in neurons of the brain and spinal cord resulting in dysfunction and the eventual cell death. The acute, infantile variant of Tay-Sachs disease is characterized by developmental retardation followed by seizures, dementia, and loss of motor skills, increased startle response and blindness with death by the age of 4. The juvenile (subacute), chronic, and adult-onset variants of hexosaminidase A deficiency have later onsets, slower progression, and more variable neurologic findings, including: progressive dystonia, spinocerebellar degeneration, motor neuron disease, and, in some individuals with adult-onset disease, a bipolar form of psychosis.

Mucolipidosis IV

Is a lysosomal storage disorder, characterized by severe psychomotor delay evident by the end of the first year of life and slowly progressive visual impairment during the first decade as a result of a combination of corneal clouding and retinal degeneration. Neurodegeneration is thought to occur in no more than 15% of individuals. About 5% of individuals have atypical mucolipidosis IV, manifest as less severe psychomotor retardation and/or eye findings. Although in the past, mucolipidosis IV was considered an Ashkenazi Jewish disease, currently most affected individuals are not of Ashkenazi Jewish ancestry. Mucolipidosis IV is caused by mutations in the MCOLN1gene that encodes for mucolipin-1. Most of the mutations result in the production of either a nonfunctional protein or a deficiency of mucolipin-1 which impairs transport of lipids and proteins, allowing these substances to accumulate inside lysosomes. The two variants, c.406-2A>G and 6.4 kb del (also known as g.511_6943del), account for 95% of pathogenic variants in individuals of Ashkenazi Jewish heritage.

Beta hemoglobinopathies

These are a diverse group of inherited disorders of red cell hemoglobin production characterized by mild to severe anemia. Individuals with beta hemoglobinopathies have defects in one or both of the beta-globin genes resulting in abnormal, diminished or absent beta-chain production and impaired hemoglobin synthesis. These disorders are typically inherited in an autosomal recessive fashion. Therefore, an individual who inherits one copy of an HBB gene mutation is a carrier and typically do not have significant health problems. An individual who inherits two mutated HBB genes, one from each parent, is expected to be affected with a beta hemoglobinopathy. If both members of a couple are carriers of a mutation in the same gene, the risk of having an affected child is 25% in each pregnancy; therefore, it is especially important that the reproductive partner of a carrier be offered testing. Beta hemoglobinopathies include sickle cell disease, beta thalassemia, hemoglobin C disease, hemoglobin E disease and other disorders in which the hemoglobin molecule is unstable or has altered oxygen affinity.

In sickle cell disease the amino acid glutamine at position 6 of the beta globin protein is replaced with the amino acid valine (Glu6Val or E6V) resulting in the production of hemoglobin S (HbS). In low oxygen environments, HbS molecules stick together and form long, rigid molecules that bend red blood cells into a sickle (crescent) shape. These sickle-shaped cells die prematurely, which leads to anemia. The sickle-shaped cells are also rigid and can block small blood vessels, causing severe pain and organ damage.

HBB gene mutations that decrease or eliminate beta-globin production result in beta-thalassemia where the reduced amount of hemoglobin, disrupts red blood cells development and decreases the amount of oxygen delivery to tissues.

Phenylketonuria

Phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels phenylalanine in the blood and urine. Phenylalanine is an essential amino acid that can only be obtained from the diet. The disorder is caused by mutations in the PAH gene that result in a deficiency of the enzyme phenylalanine hydroxylase in the liver where it converts phenylalanine to tyrosine. This deficiency results in intolerance to the dietary intake of phenylalanine and produces a spectrum of disorders. The risk of adverse outcome varies based on the degree of PAH deficiency. Without effective therapy, most individuals with severe PAH deficiency, known as classic PKU, develop profound and irreversible intellectual disability. Affected individuals on an unrestricted diet who have phenylalanine levels above normal but below 1,200 μmol/L (20 mg/dL) are at much lower risk for impaired cognitive development in the absence of treatment. The mainstay of treatment for PKU is dietary restriction of phenylalanine.

Galactosemia

Galactosemia is a disorder of galactose metabolism caused by mutations of either the GALT, GALK1 or GALE genes. These genes encode enzymes that break down galactose into glucose, and other molecules that the body can store or use for energy. A deficiency of one or more of these enzymes results in elevated galactose levels in the blood, elevated galactose-1-phosphate in red cells and increased galactitol in blood and urine. Mutations in the GALT gene cause classic galactosemia (type I). Most of the mutations markedly decrease or eliminate the activity of the enzyme Galactose-1-phosphate uridyl transferase thus preventing the normal processing of galactose in the diet. Galactosemia type II results from mutations in the GALK1 gene, while mutations in the GALE gene underlie galactosemia type III. Like the enzyme produced from the GALT gene, the enzymes made from the GALK1 and GALE genes play important roles in processing galactose. A shortage of any of these critical enzymes allows galactose and related compounds to build up to toxic levels in the body. The accumulation of these substances damages tissues and organs, leading to the characteristic features of galactosemia.

Panel Components

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)

  • As an aid in diagnosis of inherited disease such as cystic fibrosis, Ashkenazi Jewish-associated disorders (Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease), beta hemoglobinopathies, phenylketonuria and galactosemia
  • Carrier and prenatal screening for family members at risk
  • Helpful for obtaining an accurate diagnosis and to identify treatment options
Depending in variation (been small intragenic deletions/insertions and missense, nonsense, and splice site variants) if pathogenic and if associated with or loss or decreased function of the phenotype related to disease will be more indicative or diagnostic or consistent with the disease. Report should show variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants. The risk calculation provided is specific for the Ashkenazi Jewish population. There is considerable variability both in the carrier frequency and detection rate among different ethnic groups.

Negative for mutations analyzed (no pathogenic variants detected)

Next generation sequencing (NGS), Sanger sequencing, Genotyping by Molecular method, Allele Specific Primer Extension (ARMS).

Whole blood (EDTA), Chorionic villous (CV), amniotic fluid.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Further mutation testing for individual genes, Usher Syndrome Type IF, Usher Syndrome Type III, Nemaline Myopathy, Maple syrup urine disease, Glycogen storage disease, Familial Hyperinsulinism (FHI), Dihydrolipoamide Dehydrogenase Deficiency (DLD) , N-acetylasparatic acid (NAA), Aspartoacylase enzyme activity, β-glucosylceramidase enzyme activity, Bone marrow examination, HEX A enzymatic activity, Cytogenetic analysis (Chromosomal breakage studies and sister-chromatid exchanges [SCE] analysis), Sweat chloride test, Semen analysis, Trans epithelial nasal potential difference (NPD), complete blood count, plasma amino acids, urine amino acids, serum galactose levels, Red cell Gal-1-P levels.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login